Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00059748 |
This study will examine and test patients with neonatal onset multi-system inflammatory disease (NOMID) to learn more about the cause and course of the disease. It will study the disease signs and symptoms and the possible role of a gene called CIAS1, and it will develop a database to gather information on patients with NOMID in the United States and around the world. It will also serve as a screening protocol to offer eligible patients participation in a treatment protocol, if an appropriate one is available.
Patients with this rare disease usually develop a chronic rash in the first days to weeks of life that can affect the entire body. Almost all patients have eye problems such as inflammation, optic atrophy, or swelling of the optic nerve. Joint problems can lead to severe disability. Nervous system problems can include chronic meningitis, brain atrophy, seizures, mental retardation, migraine headaches, hearing loss and others.
Patients with NOMID whose symptoms include a rash since birth along with one of the following: joint disease or bone overgrowth; central nervous system problem, eye problems, enlarged liver and spleen, or elevated inflammatory markers (substances that indicate inflammation) may be eligible for this study.
Participants will be admitted to the NIH Clinical Center for 3 to 4 days for the following tests:
Rehabilitation evaluation to assess hand coordination, the ability to walk, and other functions.
Condition |
---|
Urticaria Arthropathy Lymphadenopathy Nervous System Anomalies |
Study Type: | Observational |
Official Title: | NOMID/CAPS, DIRA, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases |
Study Start Date: | April 2003 |
Autoinflammatory multisystem diseases are a group of diseases that are characterized by recurrent episodes of systemic inflammation as well as organ specific inflammation that can involve the skin, eyes, joints, bones, serosal surfaces, inner ear, and brain. The prominent role of IL-1 in the pathogenesis of these disorders has first become evident through the discovery of mutations in CIAS1 causing the cryopyrin-associated periodic syndromes (CAPS) including the most severe presentation Neonatal Onset Multisystem Inflammatory Disease (NOMID). We recently identified a new autoinflammatory disease DIRA (Deficiency of IL-1 Receptor Antagonist), a disease that is caused by mutations in IL1RN. Therapy with anakinra, the IL-1 receptor antagonist, can be life-saving. We plan to extend this protocol to explore additional rare diseases including the spectrum CRMO (Chronic Recurrent Multifocal Osteomyelitis), Still's disease, and Beh et's disease (BD) all of which may involve dysregulation of IL-1. In this research protocol we seek to comprehensively evaluate affected patients clinically, genetically, immunologically, and endocrinologically. In addition we intend to evaluate long term outcome and biomarkers. Eligibility for ongoing and planned treatment protocols will be determined by screening patients in this protocol. We plan to evaluate patients on a consultative basis for other autoinflammatory diseases for possible enrollment into this study.
Ages Eligible for Study: | 3 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Subjects with known or suspected diagnosis of NOMID/CAPS, DIRA, CRMO, Still's disease, Behcet's disease, and other autoinflammatory diseases will be evaluated either at the outpatient or inpatient unit of the Clinical Center as indicated.
There is:
Relatives of patients with autoinflammatory diseases may be included for genetic testing in collaboration with Dr. Daniel Kastner's laboratory.
EXCLUSION CRITERIA:
Active malignancy or any medical condition that in the opinion of the investigator would warrant exclusion
Inability to provide consent
Inability to return for follow up visits
Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
Contact: TTY | 1-866-411-1010 |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 |
Study ID Numbers: | 030173, 03-AR-0173 |
Study First Received: | May 5, 2003 |
Last Updated: | April 24, 2009 |
ClinicalTrials.gov Identifier: | NCT00059748 History of Changes |
Health Authority: | United States: Federal Government |
Central Nervous System Abnormalities Arthropathy Urticaria Papilledema |
Auto Inflammation Neonatal Onset Multisystem Imflammatory Disease NOMID |
Papilledema Skin Diseases Nervous System Malformations Joint Diseases Urticaria Inflammation Behcet Syndrome |
Lymphatic Diseases Hypersensitivity Still's Disease Musculoskeletal Diseases Hypersensitivity, Immediate Congenital Abnormalities Chronic, Infantile, Neurological, Cutaneous, Articular Syndrome |
Lymphatic Diseases Hypersensitivity Skin Diseases, Vascular Immune System Diseases Skin Diseases Musculoskeletal Diseases |
Nervous System Malformations Joint Diseases Nervous System Diseases Hypersensitivity, Immediate Urticaria Congenital Abnormalities |